Press Releases

April 22, 2024

Summary Toggle Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
April 11, 2024

Summary Toggle Endo, Inc. Announces Pricing of $1.5 billion of Senior Secured Term Loan as Part of Endo's $2.5 billion Exit Financing
April 11, 2024

Summary Toggle Endo, Inc. Announces Pricing of $1.0 billion of Senior Secured Notes
April 8, 2024

Summary Toggle Endo, Inc. Announces Proposed Private Offering of Senior Secured Notes
April 1, 2024

Summary Toggle Endo, Inc. Announces Proposed New Senior Secured Credit Facilities
March 28, 2024

Summary Toggle Paladin Labs Announces Approval of WAKIX® (pitolisant hydrochloride tablets) For Use in Pediatric Patients in Canada
March 26, 2024

Summary Toggle Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®
March 19, 2024

Summary Toggle Endo Announces Confirmation of Plan of Reorganization
March 12, 2024

Summary Toggle Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
March 6, 2024

Summary Toggle ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS
February 29, 2024

Summary Toggle Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER
January 24, 2024

Summary Toggle Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open
January 22, 2024

Summary Toggle Endo’s Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada
January 19, 2024

Summary Toggle Endo Announces New Data for Dupuytren’s Contracture Presented at the American Association for Hand Surgery Annual Meeting
December 19, 2023

Summary Toggle ENDO FILES PLAN OF REORGANIZATION TO IMPLEMENT PREVIOUSLY ANNOUNCED SALE TRANSACTION
November 30, 2023

Summary Toggle Endo Launches Unscripted Video Series With Real Peyronie's Disease Patients
November 16, 2023

Summary Toggle Endo Announces Five Presentations at the Sexual Medicine Society of North America (SMSNA) Annual Meeting
November 6, 2023

Summary Toggle ENDO REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS
November 2, 2023

Summary Toggle Endo Launches Colchicine Capsules, Generic Version of MITIGARE®
September 21, 2023

Summary Toggle Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
September 12, 2023

Summary Toggle Paladin Labs Announced Favourable CADTH Recommendation for XCOPRI™ (cenobamate tablets) Français
August 8, 2023

Summary Toggle ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS
July 20, 2023

Summary Toggle Endo Announces First Patient Enrolled in Registry of Peyronie's Disease
July 18, 2023

Summary Toggle Endo Launches Bivalirudin Injection in Ready-to-Use Vials
July 17, 2023

Summary Toggle Endo and Premier, Inc. Collaborate to Address Pitocin® (oxytocin injection, USP) Shortage
July 13, 2023

Summary Toggle Endo Presents New Data at the American Podiatric Medical Association Annual Meeting
June 29, 2023

Summary Toggle Endo Launches First Generic Version of Noxafil® (posaconazole) Injection
June 29, 2023

Summary Toggle Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada
June 26, 2023

Summary Toggle Endo Announces First Patient Enrolled in Registry of Dupuytren's Contracture
June 15, 2023

Summary Toggle Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant®
June 12, 2023

Summary Toggle Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe
June 5, 2023

Summary Toggle Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®
May 24, 2023

Summary Toggle Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials
May 8, 2023

Summary Toggle ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS
April 26, 2023

Summary Toggle Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Product in the U.S.
April 17, 2023

Summary Toggle Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program
April 3, 2023

Summary Toggle Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension
March 13, 2023

Summary Toggle Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis
March 10, 2023

Summary Toggle Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules
March 6, 2023

Summary Toggle ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS
February 6, 2023

Summary Toggle Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's Disease
December 6, 2022

Summary Toggle Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)
November 9, 2022

Summary Toggle ENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS
October 27, 2022

Summary Toggle Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool
October 7, 2022

Summary Toggle Endo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual Meeting
October 5, 2022

Summary Toggle Endo Launches Unscripted Video Series With Real Dupuytren's Contracture Patients
August 16, 2022

Summary Toggle Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation
August 9, 2022

Summary Toggle ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS
August 8, 2022

Summary Toggle Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy
July 15, 2022

Summary Toggle Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada
July 1, 2022

Summary Toggle Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor
July 1, 2022

Summary Toggle Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder
June 13, 2022

Summary Toggle Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain
June 9, 2022

Summary Toggle National Survey of Over 1,500 Men Shows More Than Half Were Unsure of How to Improve Their Mental and Sexual Health; New Partnership Aims to Change That Through Education and Free Virtual Consultations
May 5, 2022

Summary Toggle ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS
May 5, 2022

Summary Toggle Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting
May 2, 2022

Summary Toggle Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar
April 20, 2022

Summary Toggle Tennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against Endo
April 12, 2022

Summary Toggle Endo to Announce First-Quarter 2022 Financial Results
March 28, 2022

Summary Toggle Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials
March 3, 2022

Summary Toggle Endo Launches New Living Our Values Program to Recognize Outstanding Team Members
March 2, 2022

Summary Toggle Butt First: Endo Launches First Direct-to-Consumer Campaign for Qwo® (collagenase clostridium histolyticum-aaes) With 200+ Patient Events
February 28, 2022

Summary Toggle ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS
February 11, 2022

Summary Toggle Endo Comments on Default Judgment on Liability in Tennessee State Court
February 7, 2022

Summary Toggle Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles
January 25, 2022

Summary Toggle Endo to Announce Fourth Quarter and Full-Year 2021 Financial Results
January 18, 2022

Summary Toggle Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims
January 17, 2022

Summary Toggle Paladin Labs Announces the Launch of Xydalba® (dalbavancin for injection) in Canada
January 13, 2022

Summary Toggle Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism
January 11, 2022

Summary Toggle Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development
January 10, 2022

Summary Toggle Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold
January 4, 2022

Summary Toggle Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution
January 4, 2022

Summary Toggle Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference
December 23, 2021

Summary Toggle Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims
December 23, 2021

Summary Toggle Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada
December 15, 2021

Summary Toggle Endo Announces Favorable Final Ruling in California State Court Opioid Trial
November 22, 2021

Summary Toggle Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting
November 18, 2021

Summary Toggle Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection
November 17, 2021

Summary Toggle Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines
November 8, 2021

Summary Toggle Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care
November 4, 2021

Summary Toggle Endo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance
November 2, 2021

Summary Toggle California State Court Issues Tentative Ruling in Endo's Favor Following Opioid Trial
October 25, 2021

Summary Toggle Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease
October 22, 2021

Summary Toggle Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting
October 5, 2021

Summary Toggle Endo to Announce Third Quarter 2021 Financial Results
September 30, 2021

Summary Toggle Endo Presents New Investigational Collagenase Clostridium Histolyticum (CCH) Survey Data at American Society for Surgery of the Hand (ASSH) Annual Meeting
September 28, 2021

Summary Toggle Endo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims
September 22, 2021

Summary Toggle Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States
September 9, 2021

Summary Toggle Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation
August 31, 2021

Summary Toggle Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation
August 5, 2021

Summary Toggle Endo Reports Second-Quarter 2021 Financial Results And Updates 2021 Financial Guidance
August 4, 2021

Summary Toggle Endo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case
July 29, 2021

Summary Toggle Endo Presents New Investigational Collagenase Clostridium Histolyticum Data at the American Podiatric Medical Association Annual Scientific Meeting
July 22, 2021

Summary Toggle Endo Announces Agreement in Principle to Settle Tennessee State Court Case
July 15, 2021

Summary Toggle Endo Comments on Tennessee Appeals Court Orders
June 24, 2021

Summary Toggle Endo to Announce Second Quarter 2021 Financial Results
June 24, 2021

Summary Toggle Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at Cosmetic Bootcamp 2021
June 11, 2021

Summary Toggle Tennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo
June 9, 2021

Summary Toggle Paladin Labs Inc. Announces Approval of Wakix® (pitolisant) in Canada
May 12, 2021

Summary Toggle Endo to Participate at 2021 RBC Capital Markets Global Healthcare Virtual Conference
May 6, 2021

Summary Toggle Endo Reports First-Quarter 2021 Financial Results And Updates 2021 Financial Guidance
April 29, 2021

Summary Toggle Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at The Aesthetic Meeting 2021
April 27, 2021

Summary Toggle Endo Implements Board Succession Plan
April 13, 2021

Summary Toggle Endo to Announce First Quarter 2021 Financial Results
April 13, 2021

Summary Toggle Endo Announces Publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery
April 12, 2021

Summary Toggle ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada
April 7, 2021

Summary Toggle Endo Comments on Entry of Default Liability Judgment in Tennessee State Court Case
March 11, 2021

Summary Toggle Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes
March 11, 2021

Summary Toggle Endo International plc Announces Proposed Private Offering Of Senior Secured Notes
March 4, 2021

Summary Toggle Endo International plc Commences Refinancing of its Existing Term Loan
February 25, 2021

Summary Toggle Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance
February 17, 2021

Summary Toggle Endo to Participate at J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference
February 17, 2021

Summary Toggle Endo Appoints Jennifer M. Chao to Board of Directors
January 26, 2021

Summary Toggle Endo to Announce Fourth-Quarter and Full-Year 2020 Financial Results
January 5, 2021

Summary Toggle Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
January 5, 2021

Summary Toggle Endo Aesthetics Launches "Really Cellulite" Campaign
January 4, 2021

Summary Toggle Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States
December 18, 2020

Summary Toggle Endo to Participate at J.P. Morgan 39th Annual Healthcare Conference
December 2, 2020

Summary Toggle Endo Completes Acquisition of BioSpecifics
November 18, 2020

Summary Toggle Endo to Participate In Upcoming Investor Conferences
November 18, 2020

Summary Toggle Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
November 5, 2020

Summary Toggle Endo Reports Third-Quarter 2020 Financial Results And Raises Full Year 2020 Financial Guidance
November 5, 2020

Summary Toggle Endo Announces Strategic Actions to Further Position the Company for Long-Term Success
November 2, 2020

Summary Toggle Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.
October 22, 2020

Summary Toggle Envarsus® PA Once-daily Immunosuppressive Therapy for Kidney and Liver Transplant Patients is Now Reimbursed in Ontario, Quebec, Manitoba and Saskatchewan
October 19, 2020

Summary Toggle Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™
October 9, 2020

Summary Toggle Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)
October 7, 2020

Summary Toggle Endo to Announce Third Quarter 2020 Financial Results
October 6, 2020

Summary Toggle Endo Releases First Environmental, Social and Governance Report
October 1, 2020

Summary Toggle Endo Begins Shipment of Generic Kuvan® Tablets and Powder for Oral Solution (sapropterin dihydrochloride)
September 25, 2020

Summary Toggle Endo Announces Fill-Finish Manufacturing and Services Agreement for Novavax COVID-19 Vaccine Candidate
September 24, 2020

Summary Toggle Endo to Present Qwo™ (collagenase clostridium histolyticum-aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)
September 8, 2020

Summary Toggle Endo to Participate at Citi 15th Annual BioPharma Virtual Conference
August 21, 2020

Summary Toggle Endo International plc Announces The Expiration And Final Tender Results Of Its Previously Announced Tender Offer
August 17, 2020

Summary Toggle Endo International plc Commences Tender Offer For Any And All Of Its Outstanding 5.75% Senior Notes Due 2022
August 5, 2020

Summary Toggle Endo Reports Second-Quarter 2020 Financial Results
July 30, 2020

Summary Toggle Endo Announces Second Quarter 2020 Earnings Call Time Change
July 29, 2020

Summary Toggle Endo Appoints M. Christine Smith, Ph.D. to Board of Directors
July 6, 2020

Summary Toggle U.S. FDA Approves Qwo™ (collagenase clostridium histolyticum-aaes), the First Injectable Treatment for Cellulite
June 17, 2020

Summary Toggle New Harris Poll Survey Shows 60% of Women Surveyed Feel It's Their Fault They Have Cellulite
June 16, 2020

Summary Toggle Endo to Announce Second-Quarter 2020 Financial Results
June 15, 2020

Summary Toggle Endo International plc Announces Final Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations
May 29, 2020

Summary Toggle Endo International plc Announces Early Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations
May 14, 2020

Summary Toggle Endo to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
May 14, 2020

Summary Toggle Endo International plc Announces Proposed Exchange Offers And Consent Solicitations
May 7, 2020

Summary Toggle Endo Reports First-Quarter 2020 Financial Results and Provides Update Relating to COVID-19 Pandemic
April 16, 2020

Summary Toggle Endo to Announce First Quarter 2020 Financial Results
February 26, 2020

Summary Toggle Endo Reports Fourth-Quarter And Full-Year 2019 Financial Results
February 19, 2020

Summary Toggle Endo Names Blaise Coleman President and Chief Executive Officer
February 19, 2020

Summary Toggle Endo Appoints Mark G. Barberio to Board of Directors
January 27, 2020

Summary Toggle Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States
January 24, 2020

Summary Toggle Endo to Announce Fourth-Quarter and Full-Year 2019 Financial Results
January 10, 2020

Summary Toggle Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million
December 17, 2019

Summary Toggle Endo to Participate at J.P. Morgan Healthcare Conference
December 10, 2019

Summary Toggle Endo Launches Generic Version of Afinitor® (everolimus) Tablets in the United States
November 22, 2019

Summary Toggle Endo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference
November 19, 2019

Summary Toggle Endo Announces FDA's Acceptance of Original Biologics License Application (BLA) for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
November 4, 2019

Summary Toggle Endo Reports Third-Quarter 2019 Financial Results
November 4, 2019

Summary Toggle Endo Implements CEO Succession Plan
October 28, 2019

Summary Toggle Endo Aesthetics Launches New Campaign Elevating Artistry Through Scientific Innovation
October 25, 2019

Summary Toggle Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data at the 2019 Fall Meeting of the Sexual Medicine Society of North America (SMSNA)
October 24, 2019

Summary Toggle Endo Presents Data on the Use of a Standing MRI for the Evaluation of Cellulite at the American Society for Dermatologic Surgery (ASDS) Annual Meeting
October 2, 2019

Summary Toggle Endo to Announce Third-Quarter 2019 Financial Results
September 30, 2019

Summary Toggle Endo Announces Successful Culmination of Litigation Regarding FDA Compounding Policy
September 6, 2019

Summary Toggle Endo Announces Submission of Biologics License Application to FDA for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
September 5, 2019

Summary Toggle Endo Announces Execution of Final Settlement Agreement and Release Resolving "Track 1" Opioid Cases
September 5, 2019

Summary Toggle Endo to Present New XIAFLEX® (collagenase clostridium histolyticum) Data at the 2019 American Society for Surgery of the Hand's (ASSH) Annual Meeting
September 4, 2019

Summary Toggle Endo Announces Approval of First Generic Orfadin® in U.S.
September 3, 2019

Summary Toggle Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Delayed-release Tablets in the United States
August 22, 2019

Summary Toggle Football Legend John Elway Reveals He has Dupuytren's Contracture and Wants Others to Get the "Facts on Hand"
August 20, 2019

Summary Toggle Endo Announces Settlement in Principle to Resolve "Track 1" Opioid Cases
August 5, 2019

Summary Toggle Endo Reports Second-Quarter 2019 Financial Results
August 2, 2019

Summary Toggle Endo Applauds U.S. District Court Decision that Vasopressin Cannot be Used for Compounding by Outsourcing Facilities
August 1, 2019

Summary Toggle Endo Appoints Domenico Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics
July 31, 2019

Summary Toggle Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
July 11, 2019

Summary Toggle Endo to Announce Second-Quarter 2019 Financial Results
June 6, 2019

Summary Toggle Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get "In Touch" With Their Anatomy This Men's Health Month
May 17, 2019

Summary Toggle Phase 3 Data of Collagenase Clostridium Histolyticum for the Investigational Treatment of Cellulite to Be Presented at The Aesthetic Meeting 2019
May 15, 2019

Summary Toggle Endo to Participate at RBC Healthcare Conference
May 9, 2019

Summary Toggle Endo Reports First-Quarter 2019 Financial Results
May 1, 2019

Summary Toggle Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product
April 10, 2019

Summary Toggle Endo to Announce First-Quarter 2019 Financial Results
April 5, 2019

Summary Toggle Endo Begins Shipment of Authorized Generic Version of PROVENTIL® (albuterol sulfate) HFA Inhalation Aerosol in the United States
March 27, 2019

Summary Toggle Endo International plc Announces Early Tender Results of its Previously Announced Cash Tender Offers and Consent Solicitations for up to $1.5 billion Aggregate Purchase Price of its Outstanding Senior Notes
March 19, 2019

Summary Toggle Endo Announces Publication Of Collagenase Clostridium Histolyticum (CCH) Phase 2 Data In Dermatologic Surgery
March 14, 2019

Summary Toggle Endo International plc Announces an Upsizing of its Cash Tender Offers and Consent Solicitations
March 14, 2019

Summary Toggle Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes
March 14, 2019

Summary Toggle Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes
March 14, 2019

Summary Toggle Endo International plc Announces Proposed Private Offering Of Senior Secured Notes
March 4, 2019

Summary Toggle Endo to Participate at Cowen & Company 39th Annual Healthcare Conference
March 1, 2019

Summary Toggle Endo Announces FDA Decision Not to Include Vasopressin on 503B Bulks List
March 1, 2019

Summary Toggle Endo Will Showcase Late-Breaking Phase 3 CCH Data at the 2019 American Academy of Dermatology Annual Meeting
February 28, 2019

Summary Toggle Endo Reports Fourth-Quarter And Full Year 2018 Financial Results
February 27, 2019

Summary Toggle Endo Announces Termination of Acquisition Agreements with Somerset Therapeutics and Business of Affiliate Wintac Limited
February 22, 2019

Summary Toggle Paladin Labs Inc. Announces Approval of Envarsus PA™ (tacrolimus prolonged-release tablets) in Canada
February 7, 2019

Summary Toggle Endo Agrees Not To Oppose Additional Stay of FDA Litigation Following Restoration of Government Appropriations
January 25, 2019

Summary Toggle Endo to Announce Fourth-Quarter and Full-Year 2018 Financial Results
December 31, 2018

Summary Toggle Endo Announces Anticipated Further Stay of Compounding Litigation Due to Lapse of Government Appropriations
December 19, 2018

Summary Toggle Endo to Participate at J.P. Morgan Healthcare Conference
November 28, 2018

Summary Toggle Endo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference
November 26, 2018

Summary Toggle Endo to Participate at Piper Jaffray Global Healthcare Conference
November 8, 2018

Summary Toggle Endo Reports Third-Quarter 2018 Financial Results
November 7, 2018

Summary Toggle Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
October 11, 2018

Summary Toggle Endo Presents Data on the Perception and Measurement of Cellulite Severity at the American Society for Dermatologic Surgery (ASDS) Annual Meeting
September 28, 2018

Summary Toggle Endo to Announce Third-Quarter 2018 Financial Results
September 28, 2018

Summary Toggle Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label
September 24, 2018

Summary Toggle Endo Agrees to Additional Stay of FDA Litigation Following FDA's Commitment to Use Best Efforts to Finalize Vasopressin Clinical Need Determination By Year End
September 6, 2018

Summary Toggle Endo to Participate at Morgan Stanley Global Healthcare Conference
August 15, 2018

Summary Toggle Endo Lifts Temporary Stay of FDA Litigation Following the Launch of a Bulk-Compounded Vasopressin Product by a Section 503B Outsourcing Facility
August 9, 2018

Summary Toggle PGA Golfer Tim Herron Teams Up with Endo Pharmaceuticals to Encourage Parents to Get Their Own Check-Ups This Back-to-School Season
August 8, 2018

Summary Toggle Endo Reports Second-Quarter 2018 Financial Results
August 2, 2018

Summary Toggle Endo Announces Appointment of Laure Park as Senior Vice President, Investor Relations and Corporate Affairs
July 27, 2018

Summary Toggle Endo Begins Shipment of Authorized Generic Version of INVANZ® (ertapenem for injection) in the United States
July 25, 2018

Summary Toggle Bioprojet and Endo Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Pitolisant in Canada
July 20, 2018

Summary Toggle Endo to Announce Second-Quarter 2018 Financial Results
July 2, 2018

Summary Toggle Endo Begins Shipment of Authorized Generic Version of Colcrys® (colchicine, USP) in the United States
June 11, 2018

Summary Toggle Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order
May 8, 2018

Summary Toggle Endo Reports First-Quarter 2018 Financial Results
May 2, 2018

Summary Toggle Endo to Participate at the UBS Global Healthcare Conference
April 27, 2018

Summary Toggle Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot Topics Symposium At The Aesthetic Meeting 2018
April 26, 2018

Summary Toggle Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited
April 23, 2018

Summary Toggle Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease
April 19, 2018

Summary Toggle Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring
April 17, 2018

Summary Toggle Endo Receives Paragraph IV Notification on Vasostrict®
April 13, 2018

Summary Toggle Endo to Announce First-Quarter 2018 Financial Results
April 2, 2018

Summary Toggle Endo Agrees to Extend Temporary Stay of FDA Litigation
March 1, 2018

Summary Toggle Endo Obtains Preliminary Injunction Against QuVa Pharma, Inc. Preventing Marketing and Release of Vasopressin Product
February 27, 2018

Summary Toggle Endo Reports Fourth-Quarter And Full-Year 2017 Financial Results
February 6, 2018

Summary Toggle Endo Announces Initiation Of Two Pivotal Phase 3 Clinical Trials Of Collagenase Clostridium Histolyticum For The Treatment Of Cellulite
January 29, 2018

Summary Toggle Endo to Announce Fourth-Quarter 2017 Financial Results
January 24, 2018

Summary Toggle Endo Agrees to FDA's Request to Seek Temporary Litigation Stay
January 11, 2018

Summary Toggle Endo Comments on United States Attorney's Office Grand Jury Subpoena Relating to Products Containing Oxymorphone
December 28, 2017

Summary Toggle Endo to Participate at the 36th Annual J.P. Morgan Healthcare Conference
November 17, 2017

Summary Toggle Endo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference
November 9, 2017

Summary Toggle Endo Reports Third-Quarter 2017 Financial Results
November 8, 2017

Summary Toggle Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram
October 30, 2017

Summary Toggle Endo Announces Certain Preliminary Financial Results for Third-Quarter 2017 and Affirms Selected 2017 Financial Guidance
October 26, 2017

Summary Toggle Endo Files Federal Lawsuit to Obtain FDA Compliance with Drug Quality and Security Act of 2013
October 25, 2017

Summary Toggle Endo Completes Divestiture of Grupo Farmacéutico SOMAR
October 9, 2017

Summary Toggle Endo to Announce Third-Quarter 2017 Financial Results
September 26, 2017

Summary Toggle Four-Time PGA TOUR Winner Tim Herron Teams Up with Endo Pharmaceuticals to Encourage Adults to Get the Facts on Hand
August 28, 2017

Summary Toggle Endo Begins Shipment of Generic Sabril® (vigabatrin) for Oral Solution
August 22, 2017

Summary Toggle Endo to Participate at Morgan Stanley Global Healthcare Conference
August 8, 2017

Summary Toggle Endo Reports Second-Quarter 2017 Financial Results
August 7, 2017

Summary Toggle Endo Announces Agreements to Resolve Virtually All Known U.S. Mesh Product Liability Claims
July 21, 2017

Summary Toggle Endo to Restructure Manufacturing Network
July 14, 2017

Summary Toggle Endo to Announce Second-Quarter 2017 Financial Results
July 6, 2017

Summary Toggle Endo Provides Update On OPANA® ER
July 5, 2017

Summary Toggle Endo Announces Divestiture of Grupo Farmacéutico SOMAR
July 3, 2017

Summary Toggle Endo Completes Divestiture of Litha Healthcare Group
June 8, 2017

Summary Toggle Endo Response to June 8, 2017 FDA Meeting Related to OPANA® ER
June 7, 2017

Summary Toggle Endo Announces Entry of Significant Case Management Order in Mesh Multidistrict Litigation
May 26, 2017

Summary Toggle Endo to Present at Goldman Sachs 38th Annual Global Healthcare Conference
May 9, 2017

Summary Toggle Endo Reports First-Quarter 2017 Financial Results
May 1, 2017

Summary Toggle Endo to Present at UBS Global Healthcare Conference
April 25, 2017

Summary Toggle Endo to Announce First-Quarter 2017 Financial Results
April 12, 2017

Summary Toggle Endo International plc Announces Pricing of Private Offering of Senior Secured Notes
April 10, 2017

Summary Toggle Endo International plc Announces Proposed Private Offering of Senior Secured Notes
April 5, 2017

Summary Toggle Endo International plc Announces Plan to Refinance Existing Credit Agreement
March 14, 2017

Summary Toggle Endo Statement On FDA Advisory Committees' Vote Related To OPANA® ER
March 3, 2017

Summary Toggle Endo International plc To Delist Ordinary Shares From The Toronto Stock Exchange
February 28, 2017

Summary Toggle Endo Reports Fourth-Quarter And Full-Year 2016 Financial Results
February 24, 2017

Summary Toggle Endo Pharmaceuticals Inc. Issues Voluntary Nationwide Recall for One Lot of Edex® (alprostadil for injection) 10 mcg 2 Pack Carton Due to Potential Lack of Sterility Assurance
February 13, 2017

Summary Toggle Endo to Announce Fourth-Quarter and Full-Year 2016 Financial Results
January 30, 2017

Summary Toggle Endo Announces U.S. FDA Approval of Ephedrine Sulfate Injection, USP
January 26, 2017

Summary Toggle Endo Announces Actions to Drive Greater Efficiency and Business Alignment
January 23, 2017

Summary Toggle Endo Announces Agreement to Resolve Federal Trade Commission Investigation and Litigation
December 21, 2016

Summary Toggle Endo Announces Appointments and Updates to Executive Management Team
December 20, 2016

Summary Toggle Endo Announces Appointment of Blaise Coleman as Chief Financial Officer
December 19, 2016

Summary Toggle Endo to Present at the 35th Annual J.P. Morgan Healthcare Conference
December 12, 2016

Summary Toggle Endo Begins Shipment of Generic ZETIA®
December 8, 2016

Summary Toggle Endo Announces Strategic Updates for BELBUCA™ and U.S. Branded Pain Portfolio
December 6, 2016

Summary Toggle Endo Begins Shipment of Generic CellCept®
November 17, 2016

Summary Toggle Endo Announces Positive Data from Phase 2b Study of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
November 8, 2016

Summary Toggle Endo Reports Third Quarter 2016 Financial Results
November 7, 2016

Summary Toggle Endo Strengthens Leadership Team with Appointment of Two Key Executives
November 1, 2016

Summary Toggle Endo Begins Shipment of Generic SEROQUEL XR®
October 20, 2016

Summary Toggle Endo Announces Departure of Chief Financial Officer
October 18, 2016

Summary Toggle Endo to Announce Third Quarter 2016 Financial Results on November 8, 2016
September 30, 2016

Summary Toggle Endo Pharmaceuticals Presents New Phase 2 Data Evaluating the Safety and Effectiveness of XIAFLEX® (Collagenase Clostridium Histolyticum) for Dupuytren's Disease Nodules
September 23, 2016

Summary Toggle Endo Names Paul Campanelli President and Chief Executive Officer
August 18, 2016

Summary Toggle Endo's President and CEO Adopts 10b5-1 Trading Plan
August 12, 2016

Summary Toggle Endo Announces OPANA® ER Regulatory Update
August 8, 2016

Summary Toggle Endo Reports Second Quarter 2016 Financial Results
August 8, 2016

Summary Toggle Endo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals
July 18, 2016

Summary Toggle Endo to Announce Second Quarter 2016 Financial Results on August 8, 2016
June 28, 2016

Summary Toggle Endo Announces Issuance of Vasostrict® Patent
June 15, 2016

Summary Toggle Endo Announces FDA Advisory Committee Meeting For OPANA® ER
June 10, 2016

Summary Toggle Endo Announces Local Qualitest Scholarship Program Award Recipients
June 3, 2016

Summary Toggle New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain
May 25, 2016

Summary Toggle Endo Employees Participate in 3rd Annual "Endo Gives" Day of Volunteering, Giving Back to Local Communities Around the World
May 5, 2016

Summary Toggle Endo Announces Appointment of Douglas S. Ingram and Todd B. Sisitsky to its Board of Directors
May 5, 2016

Summary Toggle Endo Announces Change to Senior Management Team
May 5, 2016

Summary Toggle Endo Reports First Quarter 2016 Financial Results
May 3, 2016

Summary Toggle Endo Announces Appearances at Upcoming Conferences
May 2, 2016

Summary Toggle Endo Announces U.S. District Court Ruling Upholding OPANA® ER Intellectual Property
April 22, 2016

Summary Toggle Endo to Announce First Quarter 2016 Financial Results on May 5, 2016
March 21, 2016

Summary Toggle Endo Provides Statement Regarding Expected FDA Approval Of Generic Voltaren® Gel Product
March 10, 2016

Summary Toggle Endo Announces Presentation at Barclays Global Healthcare Conference
March 9, 2016

Summary Toggle National Sports Commentator, Dr. Jerry Punch, Together with Men's Health Network and Endo Pharmaceuticals, Encourages Men with Peyronie's Disease to Ask About the Curve
March 2, 2016

Summary Toggle Endo Provides Informational Frequently Asked Questions & Answers
February 29, 2016

Summary Toggle Endo Reports Fourth Quarter And Full Year 2015 Financial Results
February 22, 2016

Summary Toggle Endo Announces Launch Of BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain Management
February 17, 2016

Summary Toggle Endo Announces Initiation of Phase 2B Clinical Trial of Collagenase Clostridium Histolyticum in Cellulite
February 16, 2016

Summary Toggle Endo to Announce Fourth Quarter 2015 Financial Results on February 29, 2016
February 1, 2016

Summary Toggle Endo Announces the Qualitest Scholarship Program
December 21, 2015

Summary Toggle Endo Announces Appearances At Upcoming Conferences
December 14, 2015

Summary Toggle Endo Announces Extension Of U.S. Rights For Voltaren® Gel
November 25, 2015

Summary Toggle Endo Announces Appearance At The 27th Annual Piper Jaffray Healthcare Conference
November 20, 2015

Summary Toggle Endo International plc Announces Conditional Redemption of All $400,000,000 Aggregate Principal Amount Outstanding of the Two Series of 7.00% Senior Notes due 2020
November 10, 2015

Summary Toggle Endo Announces Appearance At The Stifel 2015 Healthcare Conference
November 9, 2015

Summary Toggle Endo Provides Informational Frequently Asked Questions & Answers
November 6, 2015

Summary Toggle Endo Announces It Will Enter Into Up To $250 Million Share Repurchase Program
November 5, 2015

Summary Toggle Endo Reports Third Quarter 2015 Financial Results
October 26, 2015

Summary Toggle U.S. FDA Approves BELBUCA™ (buprenorphine) Buccal Film for Chronic Pain Management
October 22, 2015

Summary Toggle Endo to Announce Third Quarter 2015 Financial Results on November 5, 2015
October 21, 2015

Summary Toggle Endo Provides Update on Use of Specialty Pharmacies
October 1, 2015

Summary Toggle Endo Completes Acquisition of Broad Portfolio of Branded and Generic Products from Aspen Holdings
September 28, 2015

Summary Toggle Endo Completes Acquisition of Par Pharmaceutical and Provides Financial Guidance
September 25, 2015

Summary Toggle Endo Announces Termination Of HSR Act Waiting Period In Connection With Its Proposed Acquisition Of Par Pharmaceutical
September 9, 2015

Summary Toggle Endo Pharmaceuticals and BioDelivery Sciences Present New Data on Investigational Product Buprenorphine HCl Buccal Film for Chronic Pain Management
September 8, 2015

Summary Toggle Endo Announces Appointment of Craig Paterson, M.D. as Chief Medical Officer
August 31, 2015

Summary Toggle Endo Pharmaceuticals Announces XIAFLEX® for Dupuytren's Contracture Formal Pricing in Japan; Commercial Launch Set for September 16, 2015
August 14, 2015

Summary Toggle Endo Announces U.S. District Court Ruling Upholding OPANA® ER Intellectual Property
August 11, 2015

Summary Toggle Endo Announces Appearance at Canaccord Genuity 35th Annual Growth Conference
August 10, 2015

Summary Toggle Endo Reports Second Quarter 2015 Financial Results
August 5, 2015

Summary Toggle Endo Divests Non-Core Business Lines from Litha Healthcare Group International Business, Enhancing Focus on Specialty Pharmaceuticals
August 4, 2015

Summary Toggle Endo Completes Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific
July 27, 2015

Summary Toggle Endo to Announce Second Quarter 2015 Financial Results on August 10, 2015
June 24, 2015

Summary Toggle Endo International plc Announces Conditional Redemption of All $499,875,000 Aggregate Principal Amount Outstanding of the Two Series of 7.00% Senior Notes due 2019
June 24, 2015

Summary Toggle Endo International plc Announces Pricing of Private Offering Of Senior Notes
June 19, 2015

Summary Toggle Endo International plc Announces Proposed Private Offering Of Senior Notes
June 10, 2015

Summary Toggle Endo International plc Closes Offering of 27,627,628 Ordinary Shares
June 4, 2015

Summary Toggle Endo International plc Prices Offering of 24,024,025 Ordinary Shares
June 2, 2015

Summary Toggle Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares
May 19, 2015

Summary Toggle First Ever Peyronie's Disease (PD) Treatment Guidelines Support Use of XIAFLEX® in Appropriate Patients
May 18, 2015

Summary Toggle Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader
May 15, 2015

Summary Toggle Endo Announces Updated XIAFLEX® Label with Recurrence and Retreatment Data in Patients with Dupuytren's Contracture
May 14, 2015

Summary Toggle Endo Pharmaceuticals and BioDelivery Sciences Present Pivotal Data from Two Phase 3 Trials Demonstrating Safety and Efficacy of Buprenorphine HCl Buccal Film for the Management of Chronic Pain
May 14, 2015

Summary Toggle Endo Employees Participate in 2nd Annual "Endo Gives" Day of Volunteering, Serving the Communities Where They Live and Work
May 11, 2015

Summary Toggle Endo Acquires Broad Portfolio of Branded and Generic Products, Expanding International Pharmaceuticals Business
May 11, 2015

Summary Toggle Endo Reports First Quarter 2015 Financial Results
May 6, 2015

Summary Toggle Endo Announces Appearance at UBS Global Healthcare Conference
April 28, 2015

Summary Toggle Endo Announces Appointment of Matthew J. Maletta as Chief Legal Officer
April 27, 2015

Summary Toggle Endo to Announce First Quarter 2015 Financial Results on May 11, 2015
March 16, 2015

Summary Toggle Endo Withdraws Proposal For Salix
March 16, 2015

Summary Toggle Endo Pharmaceuticals Announces the Launch of NATESTO™ (testosterone nasal gel), the First and Only Nasal Gel for Testosterone Replacement Therapy
March 11, 2015

Summary Toggle Endo Announces Appearance at Upcoming Conference
March 11, 2015

Summary Toggle Endo Confirms Proposal To Acquire Salix For $175.00 Per Share In Cash And Stock
March 2, 2015

Summary Toggle Endo Reports Fourth Quarter And Full Year 2014 Financial Results
March 2, 2015

Summary Toggle Endo Announces Divestiture of American Medical Systems' Men's and Prostate Health Businesses to Boston Scientific
February 23, 2015

Summary Toggle Endo Pharmaceuticals and BioDelivery Sciences Announce Acceptance of NDA for BELBUCA™ (buprenorphine HCl) Buccal Film for the Management of Chronic Pain
February 19, 2015

Summary Toggle American Medical Systems Announces 1,000th Patient Enrolled in PROPPER Registry
February 13, 2015

Summary Toggle Endo to Announce Fourth Quarter 2014 Financial Results on March 2, 2015
February 9, 2015

Summary Toggle Paladin Labs Announces the Canadian Launch of Zincofax® Spray
February 3, 2015

Summary Toggle Auxilium Announces Fundamental Change and Make-Whole Fundamental Change Relating to Outstanding Convertible Senior Notes
February 3, 2015

Summary Toggle American Medical Systems (AMS) sponsors Healthy Body Healthy Mind episode to raise awareness of Stress Urinary Incontinence and treatment options
February 2, 2015

Summary Toggle Paladin Labs Announces the Canadian Launch of Dynamiclear Rapid™
January 29, 2015

Summary Toggle Endo Completes Acquisition Of Auxilium Pharmaceuticals
January 21, 2015

Summary Toggle Endo International plc Announces Pricing of Private Offering Of Senior Notes
January 20, 2015

Summary Toggle Endo International plc Announces Proposed Private Offering Of Senior Notes
January 9, 2015

Summary Toggle Endo Announces Changes to Senior Management Team
January 5, 2015

Summary Toggle Endo Announces Retirement of Chief Legal Officer
December 23, 2014

Summary Toggle Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
December 22, 2014

Summary Toggle Endo Announces Appearances at Upcoming Conferences
December 11, 2014

Summary Toggle Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC
December 9, 2014

Summary Toggle Endo Completes Acquisition of Rights to Natesto™ Testosterone Nasal Gel
November 24, 2014

Summary Toggle Endo Acquires Rights to Natesto™ Testosterone Nasal Gel
November 20, 2014

Summary Toggle Endo Announces Launch of Generic Version of Valcyte®
November 19, 2014

Summary Toggle Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed Acquisition of Auxilium Pharmaceuticals
November 10, 2014

Summary Toggle Endo Receives Final Approval for Generic Version of Valcyte®
November 5, 2014

Summary Toggle Endo Reports Third Quarter Financial Results
October 20, 2014

Summary Toggle Endo to Announce Third Quarter 2014 Financial Results on November 5, 2014
October 9, 2014

Summary Toggle Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion
September 30, 2014

Summary Toggle Endo Reaches Master Settlement Agreements to Resolve Substantially All Remaining AMS Mesh Litigation Claims
September 22, 2014

Summary Toggle Endo International Comments On Auxilium Pharmaceutical's Rejection Of Its Acquisition Proposal
September 16, 2014

Summary Toggle Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock
September 8, 2014

Summary Toggle Top-Line Data Show the Investigational TOPAS™ System Improves Fecal Incontinence in Women
September 8, 2014

Summary Toggle Endo to Present at Morgan Stanley Global Healthcare Conference 2014
September 8, 2014

Summary Toggle Endo announces launch of Authorized Generic of FORTESTA® Gel
August 6, 2014

Summary Toggle Endo completes acquisition of DAVA Pharmaceuticals
August 5, 2014

Summary Toggle Paladin Labs Announces the Canadian Launch of Travelan®
July 31, 2014

Summary Toggle Endo Reports Second Quarter Financial Results
July 30, 2014

Summary Toggle Endo appoints Shane M. Cooke to Board of Directors
July 24, 2014

Summary Toggle Endo completes acquisition of Grupo Farmaceutico Somar®
July 16, 2014

Summary Toggle Paladin Labs Announces the Canadian Launch of Veregen®
July 15, 2014

Summary Toggle Endo to Announce Second Quarter 2014 Financial Results on July 31, 2014
July 7, 2014

Summary Toggle Endo and BioDelivery Sciences announce positive top-line results from the Phase III clinical trial of BEMA® buprenorphine in opioid-experienced patients with chronic pain
June 25, 2014

Summary Toggle Endo International plc Announces Pricing of Private Offering Of Senior Notes
June 25, 2014

Summary Toggle Endo International plc Announces Proposed Private Offering Of Senior Notes
June 24, 2014

Summary Toggle Endo to Acquire DAVA Pharmaceuticals
June 9, 2014

Summary Toggle American Medical Systems Enrolls First Patient in Embrace, a 522 Post Market Surveillance Study for the Elevate™ Anterior and Apical Prolapse System
June 2, 2014

Summary Toggle Endo Completes Sale of Early Stage Drug Discovery Portfolio
May 19, 2014

Summary Toggle Endo Completes Acquisition of Rights to Sumavel® DosePro®
May 9, 2014

Summary Toggle Endo Announces Appearances at Upcoming Conferences
May 6, 2014

Summary Toggle Endo Health Solutions Inc. Final Results and Settlement of Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
May 1, 2014

Summary Toggle Endo Reports First Quarter Financial Results
April 30, 2014

Summary Toggle Endo Health Solutions Inc. Announces Extension of Expiration Date and Reopening of Withdrawal Rights in Exchange Offers for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
April 30, 2014

Summary Toggle Endo Reaches Agreements in Principle to Settle a Substantial Majority of AMS Litigation Cases
April 30, 2014

Summary Toggle Endo Health Solutions Inc. Announces Extension of Expiration Date in Exchange Offers for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
April 29, 2014

Summary Toggle Endo to Acquire Specialty Pharmaceuticals Company Somar
April 28, 2014

Summary Toggle Endo Appoints Dr. Hemanth J. Varghese as Executive Vice President of Corporate Development and Strategy
April 24, 2014

Summary Toggle Endo Acquires Rights to Sumavel® DosePro®
April 17, 2014

Summary Toggle Endo Health Solutions Inc. Announces Receipt of Requisite Tenders and Consents in the Exchange Offers and Consent Solicitations Relating to its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7¼% Senior Notes due 2022
April 15, 2014

Summary Toggle Endo to Announce First Quarter 2014 Financial Results on May 1, 2014
April 11, 2014

Summary Toggle Endo Health Solutions Inc. Announces Extension of Consent Date and Expiration Date in Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7-1/4% Senior Notes due 2022
April 9, 2014

Summary Toggle Louis Van Amstel, Former Dancing with the Stars Professional, Joins "Making Your Move" Campaign to Raise Awareness of Osteoarthritis
April 8, 2014

Summary Toggle Endo Health Solutions Inc. Amends Exchange Offers and Consent Solicitations for its 7% Senior Notes due 2019, 7.00% Senior Notes due 2020 and 7 1/4% Senior Notes due 2022
March 28, 2014

Summary Toggle Endo International plc Announces Endo Health Solutions Inc. Will Commence Exchange Offers
March 18, 2014

Summary Toggle Endo International plc [ENDP] to Ring The NASDAQ Stock Market Opening Bell
March 7, 2014

Summary Toggle Endo Announces Appointment of Dr. Susan Hall as New Chief Scientific Officer and Global Head of R&D and Quality
March 6, 2014

Summary Toggle U.S. FDA Approves AVEED™ (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy For Men Living With Hypogonadism, Or Low-T
February 28, 2014

Summary Toggle Endo Completes Acquisition of Paladin Labs
February 28, 2014

Summary Toggle Endo Reports Fourth Quarter And Full Year 2013 Financial Results
February 27, 2014

Summary Toggle Endo Health Solutions Announces Departure Of Chief Scientific Officer
February 26, 2014

Summary Toggle Endo Announces Shareholder Approval of its Acquisition of Paladin Labs
February 21, 2014

Summary Toggle Endo Announces Resolution of Government Investigation
February 20, 2014

Summary Toggle Endo to Announce Fourth Quarter 2013 Financial Results on February 28, 2014
February 19, 2014

Summary Toggle Endo Announces 2013 Non-Cash Charges
February 18, 2014

Summary Toggle Endo Announces South African Competition Act Compliance and Approval Under the Investment Canada Act in Connection with Its Proposed Acquisition of Paladin Labs
February 3, 2014

Summary Toggle Endo Completes Divestiture Of HealthTronics
February 3, 2014

Summary Toggle Endo Completes Acquisition of Specialty Generics Company Boca Pharmacal
January 29, 2014

Summary Toggle Endo Confirms Court Upholds FROVA Patent
January 23, 2014

Summary Toggle Endo and BioDelivery Sciences Announce Positive Top-Line Results from the Phase III Clinical Trial of BEMA Buprenorphine in Opioid Naive Patients with Chronic Pain
January 21, 2014

Summary Toggle Endo Merger Agreement with NuPathe Terminated
January 9, 2014

Summary Toggle Endo Announces Divestiture Of HealthTronics
January 3, 2014

Summary Toggle Endo Health Solutions to Present at the 32nd Annual J.P. Morgan Healthcare Conference